Synopsis
Synopsis
0
KDMF
0
NDC API
0
VMF
0
FDF
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
0
News #PharmaBuzz
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. Ca Lactate
1. 814-80-2
2. Calcium Dilactate
3. Calphosan
4. Hemicalcium L-lactate
5. Lactic Acid, Calcium Salt (2:1)
6. Calcium;2-hydroxypropanoate
7. Calcium 2-hydroxypropanoate
8. Propanoic Acid, 2-hydroxy-, Calcium Salt (2:1)
9. 2-hydroxypropanoic Acid Calcium Salt
10. 5743-48-6
11. Calcium Lactate Anhydrous
12. Calcium 2-hydroxypropanoate (1:2)
13. 63690-56-2
14. Calcium (as Lactate)
15. Calcium Bis(2-hydroxypropanoate)
16. Calcium Lactate, Anhydrous
17. Ins No.327
18. 28305-25-1
19. 2urq2n32w3
20. Ins-327
21. Ins-327-
22. Dsstox_cid_236
23. Conclyte Calcium
24. E-327
25. Dsstox_rid_75451
26. Dsstox_gsid_20236
27. Ca Lactate
28. Cas-814-80-2
29. Calcium Lactate [usan:jan]
30. Ccris 3669
31. Hsdb 976
32. Einecs 212-406-7
33. Unii-2urq2n32w3
34. Ai3-04468
35. Calcium Dl-lactate
36. Einecs 227-266-2
37. Calcium Lactate [ii]
38. Calcium Lactate [mi]
39. Calcium Lactate [fcc]
40. Calcium Lactate [hsdb]
41. Calcium Lactate [inci]
42. Calcium Lactate (1:2)
43. Calcium Lactate [vandf]
44. Ec 212-406-7
45. Calcium Lactate [who-dd]
46. Schembl4319
47. Calcium (as Lactate) [vandf]
48. Chembl2106111
49. Dtxsid0020236
50. Hy-b2227a
51. Calcium Lactate [usp-rs]
52. Lactic Acid Calcium Salt (2:1)
53. Amy37027
54. Tox21_201378
55. Tox21_302896
56. Bis(2-hydroxypropanoic Acid) Calcium
57. Mfcd00035548
58. Akos015837558
59. Calcium Lactate [ep Monograph]
60. Db13231
61. Ncgc00256365-01
62. Ncgc00258929-01
63. (+/-)-lactic Acid, Calcium Salt (2:1)
64. Db-023012
65. Cs-0021602
66. Ft-0623403
67. Ft-0652809
68. F16480
69. Calcium Lactate Anhydrous [usp Monograph]
70. Calcium Lactate, Anhydrous [ep Impurity]
71. A840142
72. Q419693
73. L(+) Lactic Acid Calcium Salt Pentahydr. 98%, Fcc
Molecular Weight | 218.22 g/mol |
---|---|
Molecular Formula | C6H10CaO6 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 0 |
Exact Mass | 218.0103289 g/mol |
Monoisotopic Mass | 218.0103289 g/mol |
Topological Polar Surface Area | 121 Ų |
Heavy Atom Count | 13 |
Formal Charge | 0 |
Complexity | 53.5 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 3 |
EXPTL USE: ORAL ADMIN OF CALCIUM LACTATE (7.7 G) LOWERED PLASMA PARATHYROID HORMONE BY 40-43% & DECR URINARY EXCRETION OF CYCLIC ADENOSINE MONOPHOSPHATE BY 30-54% IN SKELETAL-TYPE HYPERPARATHYROIDISM BUT NOT IN OTHER TYPES OR IN CONTROLS.
SOHN HE ET AL; NIPPON NAIBUMPI GAKKAI ZASSHI 58(2) 110 (1982)
EXPTL USE: HIGH DOSES OF ORAL CALCIUM LACTATE DECR URINARY CYCLIC ADENOSINE MONOPHOSPHATE EXCRETION IN BORDERLINE CASES OF UROLITHIC AND CHEM HYPERPARATHYROIDISM.
SOHN HE ET AL; NIPPON NAIBUMPI GAKKAI ZASSHI 58(2) 110 (1982)
May be used to treat mild hypocalcemia and for maintenance therapy. /From table/
American Medical Association, Council on Drugs. AMA Drug Evaluations Annual 1994. Chicago, IL: American Medical Association, 1994., p. 2246
MEDICATION (VET): IN CALCIUM THERAPY
SRI
CALCIUM GLUCONATE & BOROGLUCONATE ARE CONSIDERED TO BE SIGNIFICANTLY LESS TOXIC THAN THE LACTATE OR THE CHLORIDE.
Humphreys, D.J. Veterinary Toxicology. 3rd ed. London, England: Bailliere Tindell, 1988., p. 28
Indicated for use as the nutritional supplement.
Both components of calcium lactate, calcium ion and lactic acid, play essential roles in the human body as a skeletal element an energy source, respectively.
A - Alimentary tract and metabolism
A12 - Mineral supplements
A12A - Calcium
A12AA - Calcium
A12AA05 - Calcium lactate
Absorption
In order to be absorbed, calcium must be in its freely soluble form (Ca2+) or bound to a soluble organic molecule. Calcium absorption mainly occurs at the duodenum and proximal jejunum due to more acidic pH and the abundance of the calcium binding proteins. The mean calcium absorption is about 25% of calcium intake (range is 10 40%) in the small intestine, and is mediated by both passive diffusion and active transport.
Route of Elimination
Following oral administration to a human volunteer, 20 to 30% of a dose of lactic acid of up to 3000 mg was excreted via the urine during a period of 14 hours.
Volume of Distribution
The majority of calcium absorbed (99%) is stored in the skeleton and teeth for structural integrity.
Clearance
No pharmacokinetic data available.
In hepatic gluconeogenesis, lactic acid is converted to glucose. Lactic acid may be further catabolyzed in the lactic acid cycle.
RUMINAL INGESTA FROM COWS FED 2.5 L GRAIN-ALFALFA HAY MIXT PROVIDING 545 G OF SODIUM LACTATE & CALCIUM LACTATE DAILY INCUBATED WITH SODIUM LACTATE OR 17 POLY LACTIC ACID. ACETATE WAS PRIMARY END PRODUCT BUT OXIDN OF LACTATE CAUSED SYNTH OF BUTYRATE FROM ACETATE.
SATTER LD, ESDALE WJ; APPL MICROBIOL 16(5) 680 (1968)
No pharmacokinetic data available.
In aqueous environments such as the gastrointestinal (GI) tract, calcium lactate will dissociate into calcium cation and lactic acid anions, the conjugate base of lactic acid. Lactic acid is a naturally-occurring compound that serves as fuel or energy in mammals by acting as an ubiquitous intermediate in the metabolic pathways. Lactic acid diffuses through the muscles and is transported to the liver by the bloodstream to participate in gluconeogenesis.
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 35941
Submission : 2021-05-27
Status : Active
Type : II
Registration Number : 304MF10053
Registrant's Address : Shili Industrial Zone, Guangshui City, Hubei Province, China
Initial Date of Registration : 2022-03-10
Latest Date of Registration : --
Registration Number : 218MF11017
Registrant's Address : 18-23 Yoshinocho, Suita City, Osaka Prefecture
Initial Date of Registration : 2006-12-27
Latest Date of Registration : --
Certificate Number : R1-CEP 2011-157 - Rev 00
Issue Date : 2018-06-19
Type : Chemical
Substance Number : 468
Status : Valid
Registration Number : 222MF10054
Registrant's Address : Osaka Prefecture, Osaka City, Chuo Ward, Doshomachi 2-1-5
Initial Date of Registration : 2010-02-12
Latest Date of Registration : --
Date of Issue : 2022-06-07
Valid Till : 2022-07-07
Written Confirmation Number : WC-0104A5-A6
Address of the Firm :
Registration Number : 217MF10524
Registrant's Address : Tokushima Prefecture Naruto City Setocho Myojin Maruyama 85-1
Initial Date of Registration : 2005-09-07
Latest Date of Registration : --
Market Place
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Calcium Lactate API manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Calcium Lactate API, including repackagers and relabelers. The FDA regulates Calcium Lactate API manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Calcium Lactate API API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Calcium Lactate API manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Calcium Lactate API supplier is an individual or a company that provides Calcium Lactate API active pharmaceutical ingredient (API) or Calcium Lactate API finished formulations upon request. The Calcium Lactate API suppliers may include Calcium Lactate API API manufacturers, exporters, distributors and traders.
click here to find a list of Calcium Lactate API suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Calcium Lactate API DMF (Drug Master File) is a document detailing the whole manufacturing process of Calcium Lactate API active pharmaceutical ingredient (API) in detail. Different forms of Calcium Lactate API DMFs exist exist since differing nations have different regulations, such as Calcium Lactate API USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Calcium Lactate API DMF submitted to regulatory agencies in the US is known as a USDMF. Calcium Lactate API USDMF includes data on Calcium Lactate API's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Calcium Lactate API USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Calcium Lactate API suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Calcium Lactate API Drug Master File in Japan (Calcium Lactate API JDMF) empowers Calcium Lactate API API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Calcium Lactate API JDMF during the approval evaluation for pharmaceutical products. At the time of Calcium Lactate API JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Calcium Lactate API suppliers with JDMF on PharmaCompass.
A Calcium Lactate API CEP of the European Pharmacopoeia monograph is often referred to as a Calcium Lactate API Certificate of Suitability (COS). The purpose of a Calcium Lactate API CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Calcium Lactate API EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Calcium Lactate API to their clients by showing that a Calcium Lactate API CEP has been issued for it. The manufacturer submits a Calcium Lactate API CEP (COS) as part of the market authorization procedure, and it takes on the role of a Calcium Lactate API CEP holder for the record. Additionally, the data presented in the Calcium Lactate API CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Calcium Lactate API DMF.
A Calcium Lactate API CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Calcium Lactate API CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Calcium Lactate API suppliers with CEP (COS) on PharmaCompass.
A Calcium Lactate API written confirmation (Calcium Lactate API WC) is an official document issued by a regulatory agency to a Calcium Lactate API manufacturer, verifying that the manufacturing facility of a Calcium Lactate API active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Calcium Lactate API APIs or Calcium Lactate API finished pharmaceutical products to another nation, regulatory agencies frequently require a Calcium Lactate API WC (written confirmation) as part of the regulatory process.
click here to find a list of Calcium Lactate API suppliers with Written Confirmation (WC) on PharmaCompass.
Calcium Lactate API Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Calcium Lactate API GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Calcium Lactate API GMP manufacturer or Calcium Lactate API GMP API supplier for your needs.
A Calcium Lactate API CoA (Certificate of Analysis) is a formal document that attests to Calcium Lactate API's compliance with Calcium Lactate API specifications and serves as a tool for batch-level quality control.
Calcium Lactate API CoA mostly includes findings from lab analyses of a specific batch. For each Calcium Lactate API CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Calcium Lactate API may be tested according to a variety of international standards, such as European Pharmacopoeia (Calcium Lactate API EP), Calcium Lactate API JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Calcium Lactate API USP).
LOOKING FOR A SUPPLIER?